Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Zamboni

Showing results (131-140 of 180) with videos related to

Pageof 18
Sort By:
Journal of Pediatric Hematology/Oncology|November 1, 1996
Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group studyD G Tubergen, C F Stewart, C B Pratt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumorsMarwan G Fakih, Patrick J Creaven, Nithya Ramnath, et al.
Journal of the National Cancer Institute|February 4, 2012
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapyPatrick J Roberts, John E Bisi, Jay C Strum, et al.
Nano Letters|February 21, 2014
Particle replication in nonwetting templates nanoparticles with tumor selective alkyl silyl ether docetaxel prodrug reduces toxicityKevin S Chu, Mathew C Finniss, Allison N Schorzman, et al.
The Oncologist|September 21, 2012
Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumorsAustin J Combest, Patrick J Roberts, Patrick M Dillon, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 31, 2025
Combinatorial treatment of glioblastoma with temozolomide (TMZ) plus 5-ethynyl-2'-deoxyuridine (EdU)Humeyra Kaanoglu, Yasemin K Akyel, Adebimpe Adefolaju, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumorClinton F Stewart, Lisa C Iacono, Murali Chintagumpala, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|December 11, 2012
Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograftKevin S Chu, Warefta Hasan, Sumit Rawal, et al.
Cancer Chemotherapy and Pharmacology|March 26, 2011
Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancerWilliam C Zamboni, Austin J Combest, Julie A DeLoia, et al.
Cancer Chemotherapy and Pharmacology|September 4, 2012
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumorsJeffrey R Infante, Vicki L Keedy, Suzanne F Jones, et al.
Pageof 18

Showing results (131-140 of 180) with videos related to

Sort By:
Pageof 18
Journal of Pediatric Hematology/Oncology|November 1, 1996
Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group studyD G Tubergen, C F Stewart, C B Pratt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumorsMarwan G Fakih, Patrick J Creaven, Nithya Ramnath, et al.
Journal of the National Cancer Institute|February 4, 2012
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapyPatrick J Roberts, John E Bisi, Jay C Strum, et al.
Nano Letters|February 21, 2014
Particle replication in nonwetting templates nanoparticles with tumor selective alkyl silyl ether docetaxel prodrug reduces toxicityKevin S Chu, Mathew C Finniss, Allison N Schorzman, et al.
The Oncologist|September 21, 2012
Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumorsAustin J Combest, Patrick J Roberts, Patrick M Dillon, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 31, 2025
Combinatorial treatment of glioblastoma with temozolomide (TMZ) plus 5-ethynyl-2'-deoxyuridine (EdU)Humeyra Kaanoglu, Yasemin K Akyel, Adebimpe Adefolaju, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumorClinton F Stewart, Lisa C Iacono, Murali Chintagumpala, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|December 11, 2012
Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograftKevin S Chu, Warefta Hasan, Sumit Rawal, et al.
Cancer Chemotherapy and Pharmacology|March 26, 2011
Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancerWilliam C Zamboni, Austin J Combest, Julie A DeLoia, et al.
Cancer Chemotherapy and Pharmacology|September 4, 2012
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumorsJeffrey R Infante, Vicki L Keedy, Suzanne F Jones, et al.
Pageof 18